JP7051906B2 - ペクチン-ドキソルビシン共役化合物及びその調製方法と用途 - Google Patents
ペクチン-ドキソルビシン共役化合物及びその調製方法と用途 Download PDFInfo
- Publication number
- JP7051906B2 JP7051906B2 JP2019564079A JP2019564079A JP7051906B2 JP 7051906 B2 JP7051906 B2 JP 7051906B2 JP 2019564079 A JP2019564079 A JP 2019564079A JP 2019564079 A JP2019564079 A JP 2019564079A JP 7051906 B2 JP7051906 B2 JP 7051906B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pectin
- doxorubicin
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
Description
さらに、dはp‐アミノベンジルオキシカルボニル基(PABC)である。
本発明はまた、上記のペクチン-ドキソルビシン共役化合物を用いて、がん治療薬を調製する用途を開示している。
化合物1(150g、0.44mol)を1.5LのTHFに溶解し、順にNHS(56g、0.49mol)、DCC(137g、0.66mol)を加え、室温で一晩撹拌し、濾過し、固体をジクロロメタンで2回洗浄し、濾液を濃縮乾固し、再結晶して、化合物2の純品を得た。
柑橘系のペクチン(市販の原料)2gを200ml(0.2mol/L)の希硝酸溶液に溶かし、85℃(内温83℃、外温90℃)に昇温し、85℃(内温は83℃)になった時点で時間計測を開始し、約2h後に加熱を停止し、室温に冷却した後、反応液を800mlの無水エタノールに滴下し、膜ろ過、洗浄、真空乾燥して化合物10を得た。
600mgの化合物11を丸底フラスコに入れ、3-アミノ-1-プロパノール(粘稠状液体)3.16gを加えて2日間撹拌し、反応時間が48hを超えた後、澄んだ粘稠状反応液をゆっくりと無水エタノールに滴下し、撹拌、濾過、洗浄、真空乾して化合物12を得た。
化合物13を秤量し、DMFとDMSOの混合溶液に完全に溶解し、化合物9を加えて、撹拌して均一になった後、DIEAを加え、室温で24h反応させた後、HPLCでドキソルビシンとその誘導体が検出されなくなるまで、溶液を直接DMSO-水勾配で透析した後、透析液を凍結乾燥してペクチン-ドキソルビシン共役化合物を得た。
本発明によって調製されたペクチン-ドキソルビシン共役化合物(実施例1-13により調製したもの)は、体内でEPR効果によって腫瘍組織内に蓄積される。受動的な標的指向性目的を達成するため、本発明によって調製されたペクチン-ドキソルビシン共役化合物のマウス移植モデルに対する体内薬効を考察した。
本発明によって調製されたペクチン-ドキソルビシン共役化合物(実施例1-13により調製したもの)と既存の対照化合物(ペクチンとドキソルビシンは直接アミド結合によって結合されたもの)の治療効果を比較するために、H 22肝臓がんと4T1乳がんのマウスモデルを選択して比較した。
Claims (9)
- 式(I)の構造を有することを特徴とするペクチン-ドキソルビシン共役化合物。
a-b-c-d-e (I)
ここで、aはペクチン又は修飾ペクチンであり、前記ペクチンは、ポリガラクツロン酸の含有量が90%以上であり、分子量が1-60KDの脱エステル化ペクチンであり、前記修飾ペクチンは、ポリガラクツロン酸脱エステル化ペクチンのカルボニル基と、ヒドロキシ基置換されたC2-C4のアルキルアミンで形成したアミドを、さらにペクチン炭酸エステルに活性化したものであり、
bはポリエチレングリコールPEGnであり、nは6-12の整数であり、
cはval-alaであり、
dはアミノベンジルオキシカルボニル基であり、
eはドキソルビシンである。 - aは修飾ペクチンであり、前記aの分子量は1-4KDであることを特徴とする請求項1に記載のペクチン-ドキソルビシン共役化合物。
- dはp‐アミノベンジルオキシカルボニル基、すなわちPABCであることを特徴とする請求項1に記載のペクチン-ドキソルビシン共役化合物。
- 式(13)の化合物の調製方法として、ペクチンとアルコールを反応させてエステル化ペクチンを得、さらにアミノ置換されたC2-C4のアルコールと反応させてアミドを形成した後、さらに炭酸ビス(4-ニトロフェニル)と反応させて式(13)の化合物を得ることを特徴とする請求項4に記載のペクチン-ドキソルビシン共役化合物の調製方法。
- 式(9)の化合物の調製方法として、式(5)の化合物をドキソルビシンとアルカリ性試薬の存在下で反応させて式(6)の化合物を得、式(6)の化合物をピペリジンの存在下で脱保護することにより式(7)の化合物を得、さらに式(7)の化合物をR1-b-COOHと反応させて式(8)の化合物を得、式(8)の化合物をピペリジンの存在下で脱保護することにより化合物(9)を得ることを特徴とする請求項4に記載のペクチン-ドキソルビシン共役化合物の調製方法。
ここで、式(5)の化合物はR1-c-PABCであり、式(6)の化合物はR1-c-PABC-eであり、式(7)の化合物はc-PABC-eであり、式(8)の化合物はR1-b-c-PABC-eであり、R1はフルオレニルメトキシカルボニル基Fmocである。 - 式(5)の化合物の調製方法として、式(3)の化合物を酸結合剤の存在下でp-アミノベンジルアルコールと反応させて式(4)の化合物を得、式(4)の化合物をアルカリ試薬の存在下で炭酸ビス(4-ニトロフェニル)と反応させて式(5)の化合物を得ることを特徴とする請求項6に記載のペクチン-ドキソルビシン共役化合物の調製方法。
ここで、式(3)の化合物はR1-c-OHであり、式(4)の化合物はR1-c-PABOHであり、PABOHは4-(ヒドロキシメチル)フェニルアミノ基である。 - 前記式(3)の化合物の調製方法として、式(I)の化合物をN-ヒドロキシスクシンイミドとジシクロヘキシルカルボジイミドの存在下で反応させて式(2)の化合物を得、式(2)の化合物をアルカリ試薬の存在下でアミノ酸と反応させて式(3)の化合物を得ることを特徴とする請求項7に記載のペクチン-ドキソルビシン共役化合物の調製方法。
ここで、式(I)の化合物はR1-c1-OHであり、式(2)の化合物はR1-c1-OSuであり、Suはスクシンイミド基であり、c1はアミノ酸である。 - 請求項1-3のいずれか一項に記載のペクチン-ドキソルビシン共役化合物のがん治療薬の調製に使用する方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/091627 WO2020252648A1 (zh) | 2019-06-18 | 2019-06-18 | 一种果胶-阿霉素轭合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021532196A JP2021532196A (ja) | 2021-11-25 |
JP7051906B2 true JP7051906B2 (ja) | 2022-04-11 |
Family
ID=68370625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019564079A Active JP7051906B2 (ja) | 2019-06-18 | 2019-06-18 | ペクチン-ドキソルビシン共役化合物及びその調製方法と用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11596643B2 (ja) |
JP (1) | JP7051906B2 (ja) |
CN (1) | CN110418653B (ja) |
WO (1) | WO2020252648A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112608364B (zh) * | 2020-12-09 | 2023-08-29 | 四川瀛瑞医药科技有限公司 | 一种果胶-阿霉素轭合物及其中间体的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045163A (zh) | 2006-03-29 | 2007-10-03 | 成都市药友科技发展有限公司 | 一种高分子抗癌前药及其制备方法和用途 |
CN103044521A (zh) | 2012-12-26 | 2013-04-17 | 亚飞(上海)生物医药科技有限公司 | 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途 |
CN106334195A (zh) | 2016-09-19 | 2017-01-18 | 华中科技大学 | 一种抗癌药物羟乙基淀粉‑阿霉素偶联物及其制备方法 |
CN107737347A (zh) | 2017-11-29 | 2018-02-27 | 北京林业大学 | 一种新型双靶向果胶‑多臂聚乙二醇联合抗癌药物的制备 |
CN107955153A (zh) | 2017-11-29 | 2018-04-24 | 南京拉克森生物医药科技有限公司 | 一种聚乙二醇-去氧胆酸及其衍生物的制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9220788B2 (en) * | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
CN100569296C (zh) * | 2007-09-17 | 2009-12-16 | 重庆莱美药业股份有限公司 | 一种抗癌前药及其制备方法和用途 |
CN100588429C (zh) * | 2008-12-23 | 2010-02-10 | 重庆莱美药业股份有限公司 | 一种pH敏感型抗癌前药及其制备方法和用途 |
CN101721714B (zh) * | 2009-12-18 | 2011-12-07 | 重庆莱美药业股份有限公司 | 实体瘤被动靶向性抗癌前药及其制备方法 |
CN102232932B (zh) * | 2010-04-27 | 2013-06-05 | 重庆莱美药业股份有限公司 | 果胶-阿霉素轭合物的冻干制剂及制备方法 |
KR102102093B1 (ko) * | 2014-05-09 | 2020-04-17 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 미셀 나노복합체 |
CN105311642B (zh) * | 2014-05-28 | 2018-11-02 | 重庆莱美药业股份有限公司 | 一种果胶抗癌前药的合成工艺 |
CN105342850B (zh) | 2015-11-13 | 2019-10-18 | 重庆莱美药业股份有限公司 | 单针混药器、硬双接口及输液软袋 |
WO2018156617A2 (en) * | 2017-02-22 | 2018-08-30 | The Regents Of The University Of Michigan | Compositions and methods for delivery of polymer / biomacromolecule conjugates |
CN108452317A (zh) * | 2018-03-29 | 2018-08-28 | 北京林业大学 | 一种基于果胶/阿霉素结合物的载药纳米粒子及其制备方法 |
-
2019
- 2019-06-18 WO PCT/CN2019/091627 patent/WO2020252648A1/zh active Application Filing
- 2019-06-18 JP JP2019564079A patent/JP7051906B2/ja active Active
- 2019-06-18 US US16/636,343 patent/US11596643B2/en active Active
- 2019-06-18 CN CN201980001356.8A patent/CN110418653B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045163A (zh) | 2006-03-29 | 2007-10-03 | 成都市药友科技发展有限公司 | 一种高分子抗癌前药及其制备方法和用途 |
CN103044521A (zh) | 2012-12-26 | 2013-04-17 | 亚飞(上海)生物医药科技有限公司 | 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途 |
CN106334195A (zh) | 2016-09-19 | 2017-01-18 | 华中科技大学 | 一种抗癌药物羟乙基淀粉‑阿霉素偶联物及其制备方法 |
CN107737347A (zh) | 2017-11-29 | 2018-02-27 | 北京林业大学 | 一种新型双靶向果胶‑多臂聚乙二醇联合抗癌药物的制备 |
CN107955153A (zh) | 2017-11-29 | 2018-04-24 | 南京拉克森生物医药科技有限公司 | 一种聚乙二醇-去氧胆酸及其衍生物的制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
Carbohydrate Polymers,2017年07月01日,Vol.174,p.493-506 |
Also Published As
Publication number | Publication date |
---|---|
US20220110957A1 (en) | 2022-04-14 |
WO2020252648A1 (zh) | 2020-12-24 |
CN110418653A (zh) | 2019-11-05 |
CN110418653B (zh) | 2022-04-12 |
JP2021532196A (ja) | 2021-11-25 |
US11596643B2 (en) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7195402B2 (ja) | シリコン系薬物複合体及びその使用方法 | |
US11413281B2 (en) | Ternary conjugate of antitumor drug, and synthesis and application | |
US5773522A (en) | Polymer-bound camptothecin derivatives | |
CN108699095A (zh) | 用于癌症选择性标记和靶向的触发子可活化代谢糖前体 | |
EP2341774B1 (en) | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
JP2010526091A5 (ja) | ||
JPH10513187A (ja) | 高分子量のポリマーを基剤とするプロドラッグ | |
JP2010526091A (ja) | 癌の処置のための生物学的な標的基の改変 | |
EP2531221B1 (en) | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis | |
CN111001012A (zh) | 一种亲水碳酸酯型抗体偶联药物 | |
WO2015081821A1 (zh) | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 | |
CA3024371A1 (en) | Multi-arm polymeric targeting anticancer conjugate | |
WO2021164765A1 (zh) | 靶向递送和激活的免疫刺激性偶联复合物的制备和用途 | |
JP7051906B2 (ja) | ペクチン-ドキソルビシン共役化合物及びその調製方法と用途 | |
WO2017206477A1 (zh) | 一种高分子ca4键合药物化合物及其制备方法 | |
KR101942159B1 (ko) | 항암제와 디오스제닌의 컨쥬게이트, 이의 제조방법 및 이를 포함하는 항암용 조성물 | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN113082222B (zh) | 一种靶向肿瘤细胞线粒体的肽基纳米药物及其制备方法与应用 | |
KR100773029B1 (ko) | 수용성 미셀을 형성하는 생분해성 고리형 삼합체 포스파젠-탁솔 컨쥬게이트 항암제 및 이의 제조방법 | |
CN113995846B (zh) | 聚乙二醇偶联药物增效剂、其制备方法及用途 | |
WO2021213492A1 (zh) | 一类载药的大分子及其制备方法 | |
TWI771652B (zh) | Cd44靶向多臂偶聯物 | |
KR102162351B1 (ko) | 약물-결합 화합물 및 이의 용도 | |
CN104650342B (zh) | 多支链聚合药物前体及其应用 | |
CN109420176B (zh) | 一种邻苯二羟基高分子载体及其在构建药物复合物纳米递药系统中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220118 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220302 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220302 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220314 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220315 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7051906 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |